On June 3, Guotai Junan's research report pointed out that Aier Eye Hospital Group (300015.SZ) plans to acquire a controlling stake in 52 ophthalmology medical institutions. The total acquisition price of part of the equity of the 52 targets is RMB 1.344 billion, with a total valuation of RMB 1.929 billion and a corresponding 2023 PS of 2.02X, which is reasonably valued. After joining the listed company system in the future, it will fully leverage the advantages of the integrated platform of medical, teaching and research, and the rich experience of mergers and acquisitions, and provide systematic assistance and precise support through the comprehensive capabilities of the group's professional learning groups, business units and various provinces and regions to continuously improve the operational status, market position, and profitability of the target companies. It is expected to accelerate the contribution to performance in the future. The target price is maintained at RMB 15.91, corresponding to a 2024 PE of 37X, and the rating is maintained as "shareholding".